Media coverage about Minerva Neurosciences (NASDAQ:NERV) has been trending somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Minerva Neurosciences earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 47.5039357878282 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Minerva Neurosciences (NASDAQ:NERV) traded down $0.05 during mid-day trading on Monday, reaching $5.45. The company had a trading volume of 130,900 shares, compared to its average volume of 240,579. Minerva Neurosciences has a 1 year low of $4.80 and a 1 year high of $11.15. The stock has a market cap of $210.92, a P/E ratio of -4.87 and a beta of 1.49.
Several research firms have weighed in on NERV. ValuEngine lowered Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. BidaskClub upgraded Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $13.94.
In other news, CFO Geoff Race sold 5,829 shares of the business’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $5.79, for a total value of $33,749.91. Following the completion of the transaction, the chief financial officer now owns 197,698 shares of the company’s stock, valued at approximately $1,144,671.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 12,590 shares of company stock valued at $73,073. 21.60% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/19/minerva-neurosciences-nerv-getting-somewhat-favorable-news-coverage-report-shows.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.